Nadim Nasrallah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nadim Nasrallah has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Christelle Lattouf
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD
2 shared publications- Gary Gerstenblith
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD
2 shared publications - Tarek Harb
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD
2 shared publications - Thorsten M. Leucker
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD
2 shared publications - Allison Gamboa Hays
Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
1 shared publication - Charalambos Antoniades
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 6 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
Vericiguat Improves MRI-Assessed Coronary Endothelial Function in Patients with the Metabolic Syndrome and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study
Aims: Impaired coronary endothelial function (CEF) is an early manifestation of coronary atherosclerosis and contributes to the development and progression of the disease. In patients with diabetes or the metabolic syndrome, diminished nitric oxide (NO) signaling may impair CEF. We evaluated whether pharmacologic stimulation of the nitric oxide–soluble guanylate cyclase (NO–sGC)–cyclic guanosine monophosphate (cGMP) pathway with vericiguat, which stimulates sGC and improves the sensitivity of sGC to NO, improves CEF assessed non-invasively by magnetic resonance imaging (MRI). Methods and Results: In this prospective, randomized, double-blind, placebo-controlled trial, 34 participants with metabolic syndrome or type 2 diabetes mellitus and impaired CEF were randomized to vericiguat (n = 23) or placebo (n = 11). Thirty-two participants (21 vericiguat and 11 placebo) completed baseline and follow-up MRI assessment of CEF, quantified as the percentage change in coronary artery cross-sectional area (CSA) from the value at rest to the one during isometric handgrip exercise. Baseline demographic, clinical, and imaging characteristics were similar between groups. CEF improved significantly with vericiguat, with the mean ± SD stress-induced change in CSA increasing from −6.8 ± 6.7% at baseline to +3.1 ± 8.5% at follow-up (within-group P = 0.0002). In contrast, CEF in the placebo-treated participants demonstrated a smaller, and non-significant improvement (−7.4 ± 8.5% to +1.4 ± 12.6%; within-group P = 0.051). Findings remained consistent after exclusion of participants initiating or intensifying GLP-1 receptor agonists or PCSK9 inhibitors. In multivariable analysis, achieved vericiguat dose was independently associated with improved coronary endothelial function (β = 6.34; 95% confidence interval 0.01–12.67; P = 0.0497). Adverse events were similar between the two groups. Conclusion: Vericiguat significantly improved MRI-assessed coronary endothelial function in patients with metabolic syndrome or type 2 diabetes and baseline coronary endothelial dysfunction. These findings provide direct in vivo evidence that pharmacologic stimulation of the NO–sGC–cGMP pathway improves coronary vasoreactivity and support MRI-derived coronary endothelial function as a promising translational imaging biomarker for evaluating vascular-targeted therapies.
- 6 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
Open AccessVericiguat Improves MRI-Assessed Coronary Endothelial Function in Patients with the Metabolic Syndrome and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study
Aims: Impaired coronary endothelial function (CEF) is an early manifestation of coronary atherosclerosis and contributes to the development and progression of the disease. In patients with diabetes or the metabolic syndrome, diminished nitric oxide (NO) signaling may impair CEF. We evaluated whether pharmacologic stimulation of the nitric oxide–soluble guanylate cyclase (NO–sGC)–cyclic guanosine monophosphate (cGMP) pathway with vericiguat, which stimulates sGC and improves the sensitivity of sGC to NO, improves CEF assessed non-invasively by magnetic resonance imaging (MRI). Methods and Results: In this prospective, randomized, double-blind, placebo-controlled trial, 34 participants with metabolic syndrome or type 2 diabetes mellitus and impaired CEF were randomized to vericiguat (n = 23) or placebo (n = 11). Thirty-two participants (21 vericiguat and 11 placebo) completed baseline and follow-up MRI assessment of CEF, quantified as the percentage change in coronary artery cross-sectional area (CSA) from the value at rest to the one during isometric handgrip exercise. Baseline demographic, clinical, and imaging characteristics were similar between groups. CEF improved significantly with vericiguat, with the mean ± SD stress-induced change in CSA increasing from −6.8 ± 6.7% at baseline to +3.1 ± 8.5% at follow-up (within-group P = 0.0002). In contrast, CEF in the placebo-treated participants demonstrated a smaller, and non-significant improvement (−7.4 ± 8.5% to +1.4 ± 12.6%; within-group P = 0.051). Findings remained consistent after exclusion of participants initiating or intensifying GLP-1 receptor agonists or PCSK9 inhibitors. In multivariable analysis, achieved vericiguat dose was independently associated with improved coronary endothelial function (β = 6.34; 95% confidence interval 0.01–12.67; P = 0.0497). Adverse events were similar between the two groups. Conclusion: Vericiguat significantly improved MRI-assessed coronary endothelial function in patients with metabolic syndrome or type 2 diabetes and baseline coronary endothelial dysfunction. These findings provide direct in vivo evidence that pharmacologic stimulation of the NO–sGC–cGMP pathway improves coronary vasoreactivity and support MRI-derived coronary endothelial function as a promising translational imaging biomarker for evaluating vascular-targeted therapies.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (9)
Coronary Inflammation Is Associated With Plaque Progression in Men With HIV
BACKGROUND: People with HIV are at elevated risk for atherosclerotic cardiovascular disease despite viral suppression, suggesting contributions from nontraditional mechanisms. Coronary vascular inflammation may play a role, but its relationship to plaque progression remains incompletely defined. The perivascular fat attenuation index (FAI) score, derived from coronary computed tomography angiography, is associated with vascular inflammation. We evaluated whether coronary inflammation is associated with the incidence and progression of coronary plaque and whether these relationships differ by HIV status. METHODS: A total of 504 men (n=292 with HIV; n=212 without HIV) from the Multicenter AIDS Cohort Study underwent coronary computed tomography angiography over a median of 4.5 years (3.8–4.9). FAI measurements were performed on baseline scans. Changes in noncalcified, calcified, and total plaque volumes were categorized into tertiles of progression. Associations were estimated using multinomial logistic regression adjusted for interscan time and cardiovascular risk factors. Modified Poisson regression estimated incident plaque. RESULTS: Higher FAI scores in the left anterior descending (LAD) and left circumflex were associated with greater odds of belonging to the highest tertile of noncalcified (LAD odds ratio [OR], 1.83 [1.27–2.64]; left circumflex OR, 2.55 [1.66–3.91]); calcified (LAD OR, 2.62 [1.64–4.18]; left circumflex OR, 3.92 [2.36–6.51]); and total plaque progression (LAD OR, 1.81 [1.25–2.62]; left circumflex OR, 2.65 [1.71–4.10]) among men with HIV, per SD increase in FAI score after adjusting for cardiovascular risk factors, and remained significant after adjustment for baseline plaque. Higher LAD FAI score was associated with incident calcified plaque in men with HIV (RR, 1.21 [1.01–1.46]). Associations for noncalcified and calcified plaque progression were stronger in men with HIV than in men without HIV. CONCLUSIONS: Coronary inflammation, assessed by FAI, is independently associated with incident and progressive coronary plaque in men with HIV. These findings support a role for vascular inflammation in accelerated atherosclerosis in people with HIV and highlight FAI as a potential biomarker for risk stratification.
- 1 September 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 19 (9)
Open AccessCoronary Inflammation Is Associated With Plaque Progression in Men With HIV
BACKGROUND: People with HIV are at elevated risk for atherosclerotic cardiovascular disease despite viral suppression, suggesting contributions from nontraditional mechanisms. Coronary vascular inflammation may play a role, but its relationship to plaque progression remains incompletely defined. The perivascular fat attenuation index (FAI) score, derived from coronary computed tomography angiography, is associated with vascular inflammation. We evaluated whether coronary inflammation is associated with the incidence and progression of coronary plaque and whether these relationships differ by HIV status. METHODS: A total of 504 men (n=292 with HIV; n=212 without HIV) from the Multicenter AIDS Cohort Study underwent coronary computed tomography angiography over a median of 4.5 years (3.8–4.9). FAI measurements were performed on baseline scans. Changes in noncalcified, calcified, and total plaque volumes were categorized into tertiles of progression. Associations were estimated using multinomial logistic regression adjusted for interscan time and cardiovascular risk factors. Modified Poisson regression estimated incident plaque. RESULTS: Higher FAI scores in the left anterior descending (LAD) and left circumflex were associated with greater odds of belonging to the highest tertile of noncalcified (LAD odds ratio [OR], 1.83 [1.27–2.64]; left circumflex OR, 2.55 [1.66–3.91]); calcified (LAD OR, 2.62 [1.64–4.18]; left circumflex OR, 3.92 [2.36–6.51]); and total plaque progression (LAD OR, 1.81 [1.25–2.62]; left circumflex OR, 2.65 [1.71–4.10]) among men with HIV, per SD increase in FAI score after adjusting for cardiovascular risk factors, and remained significant after adjustment for baseline plaque. Higher LAD FAI score was associated with incident calcified plaque in men with HIV (RR, 1.21 [1.01–1.46]). Associations for noncalcified and calcified plaque progression were stronger in men with HIV than in men without HIV. CONCLUSIONS: Coronary inflammation, assessed by FAI, is independently associated with incident and progressive coronary plaque in men with HIV. These findings support a role for vascular inflammation in accelerated atherosclerosis in people with HIV and highlight FAI as a potential biomarker for risk stratification.